GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cynata Therapeutics Ltd (ASX:CYP) » Definitions » Common Stock

Cynata Therapeutics (ASX:CYP) Common Stock : A$81.63 Mil (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Cynata Therapeutics Common Stock?

Cynata Therapeutics's quarterly common stock increased from Dec. 2022 (A$74.90 Mil) to Jun. 2023 (A$81.63 Mil) but then stayed the same from Jun. 2023 (A$81.63 Mil) to Dec. 2023 (A$81.63 Mil).

Cynata Therapeutics's annual common stock increased from Jun. 2022 (A$74.90 Mil) to Jun. 2023 (A$81.63 Mil) but then stayed the same from Jun. 2023 (A$81.63 Mil) to Jun. 2024 (A$81.63 Mil).


Cynata Therapeutics Common Stock Historical Data

The historical data trend for Cynata Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cynata Therapeutics Common Stock Chart

Cynata Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.17 74.90 74.90 81.63 81.63

Cynata Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 74.90 74.90 81.63 81.63 81.63

Cynata Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Cynata Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
100 Cubitt Street, Level 3, Cremorne, VIC, AUS, 3121
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.

Cynata Therapeutics Headlines

No Headlines